Immunocore Holdings PLC (NAS:IMCR)

$ 31.85 0 (0%) Market Cap: 1.59 Bil Enterprise Value: 1.16 Bil PE Ratio: 0 PB Ratio: 4.28 GF Score: 66/100

Q2 2024 Immunocore Holdings PLC Earnings Call Transcript
Aug 08, 2024

$37.92 (+2.76%)

Earnings
Q4 2023 Immunocore Holdings PLC Earnings Call Transcript
Feb 28, 2024

$69.21 (-1.76%)

Earnings
Immunocore Holdings PLC at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Immunocore Holdings PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Immunocore Holdings PLC Earnings Call Transcript
Aug 10, 2023

$61.66 (-3.67%)

Earnings
Immunocore Holdings PLC at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Immunocore Holdings PLC at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Immunocore Holdings PLC at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Q4 2022 Immunocore Holdings PLC Earnings Call Transcript
Mar 01, 2023

$54.05 (-1.46%)

Earnings
Immunocore Holdings PLC at Citi Virtual Oncology Leadership Summit Transcript
Feb 22, 2023
Immunocore Holdings PLC at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Immunocore Holdings PLC at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022
Immunocore Holdings PLC at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
Immunocore Holdings PLC PRAME Investor and Analyst Event AT ESMO 2022 Transcript
Sep 09, 2022
Q2 2022 Immunocore Holdings PLC Earnings Call Transcript
Aug 10, 2022

$53.95 (+4.27%)

Earnings
Immunocore Holdings PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2022
Immunocore Holdings PLC To Discuss FDA Approval Call Transcript
Jan 26, 2022

Immunocore Holdings PLC To Discuss FDA Approval Call Transcript

Jan 26, 2022 / 01:30PM GMT

Release Date Price: $23.58 (+7.52%)

Transcript

Operator

Good day, ladies and gentlemen. Thank you for standing by. Welcome to Immunocore's FDA approval of KIMMTRAK webinar. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Brian Di Donato, CFO and Head of Strategy from Immunocore. Please go ahead, sir.

Brian R. Di Donato

Immunocore Holdings plc - CFO & Head of Strategy

Thank you, Kevin. Good morning, and good afternoon, everyone, and thank you for joining us today to discuss the FDA approval of KIMMTRAK.

Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning Immunocore's future expectations, clinical development and clinical trials, regulatory approval processes, plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purpose of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated by these forward-looking statements as a result of various

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.